Success with oncologic treatment has allowed cancer patients to experience longer cancer-
free survival gains. Unfortunately, this success has been tempered by unintended and often …

Advances in cancer therapy have resulted in significant improvement in long-term survival
for many types of cancer but have also resulted in untoward side effects associated with …

Cancer therapies, especially anthracyclines and monoclonal antibodies, have been linked
with increased rates of cardiotoxicity. The development of some cardiac side effects …

Objectives: The purpose of this study was to examine treatment practices for cancer therapy-
associated decreased left ventricular ejection fraction (LVEF) detected on echocardiography …

Cardiovascular toxicity in the form of cardiac dysfunction continues to be an obstacle for
patients with cancer. Survival and quality of life of cancer survivors are frequently affected by …

Background For multiple chemotherapeutics, cardiotoxicity is dose limiting and can lead to
substantial morbidity and mortality. Early cardiac intervention has the potential to positively …

Cancer therapy-related cardiac dysfunction (CTRCD) is one of the most feared and
undesirable side effects of chemotherapy, occurring in approximately 10% of the patients. It …

Contemporary cancer therapies have dramatically improved cancer-free and overall survival
but have been accompanied by increasing cancer treatment–related cardiovascular toxicity …

Recent advances in cancer management have improved long-term survival. Increased
longevity has been accompanied by a rise in the frequency of age-related cardiovascular …

Cardiac toxicities from cancer therapy can become evident many years after treatment, and
these late cardiac effects can have a profound impact on cancer survivors. There are a …